Our study has already validated the anti-MM activity of HDAC inhibitor LBH589 (Novartis Pharmaceuticals, USA) [97]; and a Phase I safety study of LBH589, given in combination with bortezomib, is ongoing in MM patients [98]. This evidence concerns the gene HDAC9 and Miyoshi myopathy.